FY2024 Earnings Estimate for IN8bio Issued By HC Wainwright

IN8bio, Inc. (NASDAQ:INAB) – Research analysts at HC Wainwright issued their FY2024 earnings estimates for shares of IN8bio in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of ($0.59) per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($0.52) per share. HC Wainwright also issued estimates for IN8bio’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.26) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.17) EPS and FY2028 earnings at $0.54 EPS.

IN8bio (NASDAQ:INAB) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01).

IN8bio Stock Performance

Shares of INAB stock opened at $0.34 on Friday. The stock has a market cap of $15.69 million, a PE ratio of -0.45 and a beta of -0.07. The stock has a 50-day moving average of $0.30 and a 200-day moving average of $0.67. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.84 and a quick ratio of 2.66. IN8bio has a one year low of $0.22 and a one year high of $2.48.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in IN8bio stock. Sigma Planning Corp lifted its position in shares of IN8bio, Inc. (NASDAQ:INAB) by 42.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 851,280 shares of the company’s stock after purchasing an additional 251,600 shares during the quarter. Sigma Planning Corp owned 1.82% of IN8bio worth $230,000 at the end of the most recent reporting period. 92.05% of the stock is owned by institutional investors and hedge funds.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.